Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30N2O8S |
Molecular Weight | 470.537 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)OC1=C(OC(=O)OCC)C=C(CCNC(=O)[C@H](CCSC)NC(C)=O)C=C1
InChI
InChIKey=ZLVMAMIPILWYHQ-INIZCTEOSA-N
InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/8529066
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/8529066
Docarpamine (marketed under the tradename Tanadopa) is a dopamine prodrug developed in Japan for the treatment of chronic heart failure. The drug does not cross the blood-brain barrier and shows no effect on CNS activity. It is supposed that the drug exerts its action by activating dopamine receptor D1.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2056 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11996645 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TANADOPA Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23676366
2250 mg/day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
701519
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C052143
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
74639-40-0
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
938
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106351
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
m4711
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1057820
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
SUB06344MIG
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
RPQ57D8S72
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
71137
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
6258
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
C65453
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY | |||
|
100000081864
Created by
admin on Fri Dec 15 15:28:30 GMT 2023 , Edited by admin on Fri Dec 15 15:28:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PRODRUG)